**Treatment effect on monthly expenditure on consumption items, continued...**

||**Control**||**Lower bounds**<br>|<br>|**Unadjusted**<br>|**U**<br>|**pper bounds**<br>||**IV**<br>|
|---|---|---|---|---|---|---|---|---|---|
||**mean**|(1)|(2)|(3)|(4)|(5)|(6)|(7)|(8)|
||**(standard**|||||||||
||**deviation)**|Lee(-)|(+/-).25 SD|(+/-).1 SD||(-/+).1 SD|(-/+).25 SD|Lee(+)||
|Panel B: Com|ponents of tot|al monthly|consumption ex|penditure,con|t...|||||
|Utilities||||||||||
|6 months|124.57|-11.55***|-9.39***|-4.67**|-1.93|1.63|6.35***|4.58*|-1.99|
||(66.12)|(2.57)|(2.07)|(2.06)|(2.77)|(2.07)|(2.09)|(2.72)|(4.13)|
|12 months|106.92|-4.21*|-2.97|1.97|5.16**|8.55***|13.48***|11.52***|13.95**|
||(52.64)|(2.42)|(1.80)|(1.80)|(2.55)|(1.81)|(1.84)|(2.57)|(6.74)|
|18 months|120.96|-14.21***|-14.56***|-5.13***|0.22|7.45***|16.88***|8.39**|-0.10|
||(73.21)|(3.06)|(2.00)|(1.98)|(3.57)|(1.99)|(2.03)|(3.53)|(10.11)|
|Water||||||||||
|6 months|49.38|-2.95**|-2.28*|0.22|2.17|3.55***|6.04***|5.54***|2.51|
||(33.73)|(1.39)|(1.28)|(1.28)|(1.72)|(1.28)|(1.28)|(1.71)|(2.45)|
|12 months|<br>55.40|<br>-7.49***|<br>-5.62***|<br>-2.50**|<br>-0.34|<br>1.65|<br>4.77***|<br>2.80|<br>-3.53|
||(34.44)|(1.35)|(1.26)|(1.25)|(1.73)|(1.25)|(1.26)|(1.73)|(4.46)|
|18 months|<br>59.55|<br>-7.23***|<br>-8.55***|<br>-3.77***|<br>0.05|<br>2.61***|<br>7.39***|<br>4.21**|<br>-1.35|
||(35.50)|(1.49)|(0.99)|(0.98)|(1.76)|(0.98)|(1.00)|(1.77)|(5.18)|
|Hygiene||||||||||
|6 months|82.86|-9.30***|-6.21***|-1.54|1.49|4.68**|9.35***|7.13**|1.59|
||(64.46)|(2.49)|(2.08)|(2.07)|(2.79)|(2.07)|(2.09)|(2.79)|(4.11)|
|12 months|88.86|-7.50***|-2.11|4.27*|8.28**|12.77***|19.14***|15.94***|18.51**|
||(70.67)|(2.90)|(2.55)|(2.53)|(3.59)|(2.52)|(2.54)|(3.67)|(8.87)|
|18 months|80.60|-8.45***|-12.47***|-4.40***|0.86|6.35***|14.42***|7.43**|4.25|
||(62.76)|(2.76)|(1.59)|(1.58)|(2.91)|(1.59)|(1.62)|(2.91)|(8.68)|
|Communicati|ons|||||||||
|6 months|37.88|-3.51***|-2.85***|-0.61|1.06|2.36**|4.60***|3.33***|1.65|
||(29.92)|(1.16)|(0.94)|(0.94)|(1.26)|(0.94)|(0.95)|(1.26)|(1.75)|
|12 months|37.55|-1.92*|-0.35|2.46**|4.40***|6.21***|9.02***|7.51***|9.78***|
||(31.17)|(1.08)|(1.06)|(1.04)|(1.44)|(1.04)|(1.04)|(1.47)|(3.18)|
|18 months|40.88|-3.40***|-5.93***|-1.73**|1.58|3.86***|8.06***|5.61***|6.83*|
||(31.81)|(1.29)|(0.80)|(0.79)|(1.41)|(0.79)|(0.80)|(1.39)|(4.11)|
|Transport||||||||||
|6 months|63.95|-12.57***|-9.07***|-3.29|-0.33|4.41*|10.19***|3.61|-0.77|
||(78.70)|(3.20)|(2.63)|(2.62)|(3.54)|(2.64)|(2.67)|(3.61)|(5.30)|
|12 months|61.32|-13.82***|-10.23***|-3.41|-0.22|5.68**|12.50***|5.18|-2.82|
||(77.86)|(3.26)|(2.57)|(2.58)|(3.64)|(2.60)|(2.64)|(3.70)|(9.85)|
|18 months|54.99|-8.91***|-8.05***|1.78|8.08**|14.87***|24.70***|12.30***|22.90**|
||(70.16)|(2.86)|(2.13)|(2.11)|(3.81)|(2.11)|(2.14)|(3.91)|(10.95)|
|Other(clothin|gtobacco etc|.)||||||||
|6 months|0.99|-0.00|-0.00***|-0.00|0.00|0.00***|0.01***|0.00|0.00|
||(0.04)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|
|12 months|0.99|-0.00|-0.01***|-0.00**|-0.00|0.00***|0.01***|0.00|-0.00|
||(0.04)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|
|18 months|0.99|0.00|-0.01***|-0.00***|0.00|0.00***|0.01***|0.00*|0.00|
||(0.04)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|(0.00)|
|Celebrations||||||||||
|6 months|3.47|-3.68***|-3.69***|-1.71***|-0.50|0.93|2.90***|-0.32|0.03|
||(27.62)|(0.60)|(0.58)|(0.57)|(0.77)|(0.57)|(0.57)|(0.78)|(1.07)|
|12 months|35.75|-33.45***|-22.86***|-14.67***|-9.18**|-3.75|4.43|-7.15|-24.30**|
||(96.92)<br>|(3.10)<br>|(3.31)<br>|(3.28)<br>|(4.67)<br>|(3.28)<br>|(3.29)<br>|(4.85)<br>|(11.68)<br>|
|18 months|4.00|-4.07***|-4.51***|-0.52|2.03*|4.79***|8.77***|2.49**|7.85**|
||(26.73)|(0.65)|(0.67)|(0.65)|(1.16)|(0.66)|(0.67)|(1.22)|(3.42)|

_Note: Significance level p< 0.01 - ***, 0.05 - **, 0.1 - *; Robust standard errors in parentheses; Each coefficient in this table is obtained from a different regression of the outcome on specification (1), which includes a binary treatment indicator fully interacted with the outcome at baseline and the propensity score, the model also includes strata fixed effects (n=5); all consumption expenditure and debt values are deflated across regions and months to average 2017 Turkish Lira; column (4) presents the main results using IPW and sampling weights; column (8) presents the results from instrumenting currently receiving the transfers with eligibility at baseline; columns (1) and (7) are estimated by trimming the top/bottom of the treatment group by the difference in attrition between the treatment and control, as in Lee (2009); columns (2) to (3) and (5) to (6) replace outcome values for the attritters with +/- 0.x standard deviations of their respective treatment group-wave means as in Kling and Liebmann (2004), lower bounds subtract this value from the treatment group and add it to the control group and vice versa for the upper bounds._ 51